Diacerein: Targeted Osteoarthritis Symptom and Joint Health Support
Diacerein
| Product dosage: 50 mg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 30 | $1.67 | $50.00 (0%) | 🛒 Add to cart |
| 60 | $1.23 | $100.00 $74.00 (26%) | 🛒 Add to cart |
| 90 | $1.10 | $150.00 $99.00 (34%) | 🛒 Add to cart |
| 120 | $1.01 | $200.00 $121.00 (40%) | 🛒 Add to cart |
| 180 | $0.92
Best per cap | $300.00 $165.00 (45%) | 🛒 Add to cart |
Synonyms | |||
Diacerein is a disease-modifying osteoarthritis drug (DMOAD) specifically formulated for the management of osteoarthritis, particularly of the knee and hip. As an interleukin-1 inhibitor, it works by modulating the underlying inflammatory processes that contribute to cartilage degradation and pain, rather than merely masking symptoms. This prescription medication offers a unique mechanism of action focused on slowing disease progression and improving joint function, making it a valuable option in long-term osteoarthritis management strategies under appropriate medical supervision.
Features
- Active ingredient: Diacerein 50mg
- Pharmacological class: Interleukin-1 beta inhibitor
- Presentation: Orange capsule formulation
- Administration: Oral route
- Prescription status: Requires medical prescription
- Manufacturer compliance: GMP-certified production
Benefits
- Reduces joint pain and stiffness through targeted anti-inflammatory action
- Slows cartilage degradation by inhibiting matrix metalloproteinases
- Improves physical function and mobility in osteoarthritis patients
- Demonstrates sustained therapeutic effects that persist after treatment cessation
- Modifies disease progression rather than providing purely symptomatic relief
- Shows favorable gastrointestinal tolerance profile compared to traditional NSAIDs
Common use
Diacerein is primarily indicated for the symptomatic treatment of osteoarthritis, with particular efficacy demonstrated in knee and hip osteoarthritis. It is prescribed for patients experiencing mild to moderate osteoarthritis symptoms who require long-term management strategies. The medication is typically used when conventional analgesics or NSAIDs provide insufficient relief or are poorly tolerated. Clinical evidence supports its use in reducing joint space narrowing and improving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores. Medical practitioners often consider diacerein for patients who may not be ideal candidates for continuous NSAID therapy due to gastrointestinal or cardiovascular risk factors.
Dosage and direction
The standard adult dosage is 50mg taken orally twice daily, preferably with meals to enhance absorption and minimize potential gastrointestinal discomfort. Treatment initiation typically begins with one 50mg capsule daily for the first 2-4 weeks to assess tolerance, followed by escalation to the maintenance dose of 100mg daily (50mg twice daily). The full therapeutic effect may require 2-4 weeks to manifest significantly, with optimal benefits observed after 3-6 months of continuous treatment. Administration should be consistent with regard to timing, and capsules should be swallowed whole with adequate water. Dosage adjustment may be necessary in elderly patients or those with hepatic impairment, though no specific renal dosage adjustment is typically required.
Precautions
Patients with pre-existing hepatic conditions require regular liver function monitoring, as transient increases in liver enzymes have been reported. Those with gastrointestinal disorders, particularly inflammatory bowel disease, should use diacerein with caution and under close medical supervision. Elderly patients may experience increased sensitivity to the medication and should be monitored for adverse effects more frequently. Diacerein may cause a harmless reddish discoloration of urine, which patients should be informed about to prevent unnecessary concern. The safety during pregnancy and lactation has not been established, requiring careful risk-benefit assessment. Regular ophthalmological examinations are recommended during prolonged treatment due to potential retinal changes observed in animal studies.
Contraindications
Diacerein is contraindicated in patients with known hypersensitivity to diacerein, anthraquinones, or any excipients in the formulation. It must not be used in patients with severe hepatic impairment (Child-Pugh Class C) or acute liver diseases. The medication is contraindicated during pregnancy and breastfeeding due to insufficient safety data. Patients with severe renal impairment (creatinine clearance <30 mL/min) should avoid diacerein therapy. Those with known gastrointestinal inflammatory conditions such as Crohn’s disease or ulcerative colitis should not use this medication. Concomitant use with potent CYP3A4 inducers or inhibitors is contraindicated without appropriate medical supervision.
Possible side effects
The most frequently reported adverse reactions involve the gastrointestinal system, including mild to moderate diarrhea (occurring in approximately 30-40% of patients), which often diminishes with continued treatment. Other common effects include abdominal pain, nausea, and soft stools. Hepatic reactions may manifest as transient elevations in liver enzymes, typically resolving with dosage reduction or discontinuation. Dermatological reactions including rash, pruritus, and urticaria have been reported in approximately 2-5% of patients. Some individuals may experience headache or dizziness during initial treatment phases. Rare but serious side effects include severe hepatic reactions, significant electrolyte imbalance due to persistent diarrhea, and allergic reactions requiring immediate medical attention.
Drug interaction
Diacerein demonstrates significant interaction potential with CYP3A4 substrates, inhibitors, and inducers. Concomitant use with strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) may increase diacerein exposure, necessitating dosage adjustment. CYP3A4 inducers (rifampicin, carbamazepine, St. John’s wort) may reduce diacerein efficacy. The medication may potentiate the effects of anticoagulants through protein binding displacement. Concurrent administration with other anthraquinone derivatives may increase the risk of gastrointestinal adverse effects. Diacerein may interfere with the absorption of concurrently administered medications due to its effects on gastrointestinal motility. Laboratory test interactions include potential interference with urinary glucose measurements using enzymatic methods.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed administration. Consistent dosing is important for maintaining therapeutic levels, but occasional missed doses are unlikely to significantly impact overall treatment efficacy. If multiple doses are missed, patients should consult their healthcare provider regarding dose re-titration if necessary. Maintaining a medication diary or using pill organizers can help prevent missed doses during long-term therapy.
Overdose
Cases of diacerein overdose are rare, with limited clinical data available. Symptoms may include severe gastrointestinal distress, pronounced diarrhea leading to dehydration and electrolyte imbalance, and potential hepatic toxicity. Management should focus on symptomatic and supportive care, including gastrointestinal decontamination if presented early after ingestion. Electrolyte replacement and hydration therapy may be necessary in cases of significant diarrhea. Liver function should be monitored closely, with appropriate hepatoprotective measures instituted if indicated. There is no specific antidote for diacerein overdose. Hemodialysis is unlikely to be effective due to diacerein’s high protein binding and extensive metabolism. Patients suspected of overdose should seek immediate medical attention for proper assessment and management.
Storage
Store diacerein capsules at room temperature between 15-30°C (59-86°F) in their original packaging to protect from light and moisture. Keep the medication in a tightly closed container to prevent degradation. Avoid storage in bathrooms or areas with high humidity or temperature fluctuations. Keep out of reach of children and pets to prevent accidental ingestion. Do not use capsules that show signs of physical damage, discoloration, or that are beyond their expiration date. Proper storage conditions maintain stability for typically 24-36 months from manufacturing date, as specified on the packaging.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Diacerein is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Individual response to treatment may vary, and the prescribing physician will determine the appropriate therapy based on specific patient factors. Patients should not initiate, discontinue, or modify their dosage without consulting their healthcare provider. The complete prescribing information should be reviewed before initiating therapy. While every effort has been made to ensure accuracy, medical knowledge evolves continuously, and healthcare providers should reference the most current clinical guidelines and product information.
Reviews
Clinical studies demonstrate that diacerein provides significant improvement in osteoarthritis symptoms, with a systematic review of randomized controlled trials showing superior pain reduction compared to placebo and comparable efficacy to NSAIDs with better gastrointestinal tolerance. Long-term extension studies indicate sustained benefits in joint function and reduced structural progression over 3-year periods. Patient-reported outcomes consistently show improvements in quality of life measures and physical functioning. The delayed onset of action is frequently noted, with many clinicians emphasizing the importance of patient education regarding expected treatment timelines. Real-world evidence supports the favorable benefit-risk profile, particularly in patients requiring long-term osteoarthritis management who cannot tolerate continuous NSAID therapy.